We need to move the debate on open clinical trial data forward

BMJ (Online)

Volumn 345, Issue 7887, 2012, Pages

  Thompson, Matthew ^a   Heneghan, Carl ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; CLINICAL PRACTICE; CLINICAL RESEARCH; CONFIDENTIALITY; DRUG INDUSTRY; INFORMATION PROCESSING; LETTER; MEDICAL ETHICS; MEDICAL SOCIETY; PATIENT RIGHT; PRIORITY JOURNAL; REMUNERATION;

ACCESS TO INFORMATION; ANTIVIRAL AGENTS; HUMANS; OSELTAMIVIR;

EID: 84871130571     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e8351     Document Type: Letter

References (6)

1. Godlee F. Open letter to Roche about oseltamivir trial data. BMJ 2012;345:e7305. (29 October.)
2. Roche Finance. Finance report 2011:162. www.roche.com/investors/annual- reports/annual-reports-2011.htm.
3. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration. BMJ 2002;324:71.
4. Budnick N. Oregon Health and Science University may ban faculty from pharmaceutical industry speakers' bureaus. www.oregonlive.com/health/index.ssf/ 2012/11/oregon-health-science-universi-14.html.
5. Burstein HJ. Disclosing pharma payments to oncologists: what will we learn? J Natl Compr Canc Netw 2012;10:133-4.
6. Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003;289:454-65. (Pubitemid 36119966)